Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Kirsten who wrote (535)	4/3/1998 10:41:00 AM
From: Rick Strange	Read Replies (1) of 1491

Kirsten, My answer last night was a bit pompous. I was working on my taxes and that always puts me in a foul mood....sorry. I don't know if I can answer your question except to say that unique drugs that address an unfilled mass market are very rare. At least those that get FDA approval are very rare. There are some companies that have done quite well by taking existing drugs and eliminating side effects. Sepracore comes to mind, they have taken most of the mass market non sedating antihistimines and created a better molecule sans side effects. They have struck deals with companies like SGP for Claritin. SGP gets an improved product and extends their patent rights a few more years. PARS is indeed a good example of a company that has taken the existing gold standard and created a new standard with Lotemax and Alrex.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next